Background: Allergic rhinitis (AR) is a global health problem. It is the cause of major illness and disability worldwide. The present study compared Monteleukast and Levocetirizine and versus Monteleukast Fexofenadine in cases of allergic rhinitis. Materials & Methods: The present study was conducted on 80 patients of allergic rhinitis of both genders. Patients were divided into 2 groups of 40 each. Group I patients were given one tablet of montelukast 10 mg plus levocetirizine 5 mg fixed-dose combination daily and group II patients was treated with fixed-dose combination of montelukast 10 mg plus fexofenadine 120 mg once daily. Results: The mean TNSS at baseline in group I was 11.4, at 2 weeks was 5.24 and at 4 weeks was 3.28. The mean TNSS at baseline in group I was 10.5, at 2 weeks was 4.06 and at 4 weeks was 1.16. Cost-effectiveness ratio in group I was significantly lower as compared to group II recorded at 2nd and 4th weeks (P< 0.05). Nausea was seen 3 patients in group I and 1 in group II, sedation 1 in group I and 3 in group II and dryness 1 in group I and 4 in group II. The difference was significant (P< 0.05). Conclusion: Authors found that montelukast-levocetirizine group found to be better than montelukast-fexofenadine group in patients with Allergic rhinitis.
Key words: Allergic rhinitis, Levocetirizine, Montelukast